The first United States Food and Drug Administration (FDA)-approved biomarker for checkpoint inhibitors is the expression level of PD-L1, defined by positive staining of tumor cytomembrane on immunohistochemistry (IHC) slides, which directly regulates the adaptive anti-tumor immune response (Doroshow et al., 2021). The gene discussed is CD274; the disease is neoplasm.